The table below shows Viridian Therapeutics, Inc.DE's income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q3 2025
Q2 2025
Q1 2025
Q3 2024
Q2 2024
Revenue
-
-
-
-
-
-
Cost of revenue
-
-
-
-
-
-
Gross profit
-
-
-
-
-
-
R&D
-
-
-
-
-
-
SG&A
$38.68M
VRDN annual revenue (10-K history)
Viridian Therapeutics, Inc.DE reported annual revenue of $4.00M for fiscal year 2017. That is up 15.1% from $3.48M in fiscal 2016. Over the 5 fiscal years shown, annual revenue declined from $4.32M (FY 2013) to $4.00M. Figures come from the company's audited annual reports as filed with the SEC.